Larisa Girshova

Larisa Girshova

Auto-generated profile, based on publicly available information

Larisa Girshova

VA Almazov National Medical Research Center

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
LALionel Adès
Lionel Adès
LGLarisa Girshova
Larisa Girshova
VDVadim A. Doronin
Vadim A. Doronin
MCMaría Campelo
María Campelo
DVDavid Valcárcel
David Valcárcel
MSMikkael A. Sekeres
Mikkael A. Sekeres
PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS; n = 324), higher-risk chronic myelomonocytic leukemia (n = 27), or acute myeloid leukemia (AML) with 20% to 30% blasts (n = 103). The primary end point was event-free survival (EFS). In the intent-to-treat population, the median EFS was 17.7 months with pevonedistat+azacitidine vs 15.7 months with azacitidine (hazard ratio [HR], 0.968; 95% confidence interval [CI], 0.757-1.238; P = .557) and in the higher-risk MDS cohort, median EFS was 19.2 vs 15.6 months (HR, 0.887; 95% CI, 0.659-1.193; P = .431). Median overall survival (OS) in the higher-risk MDS cohort was 21.6 vs 17.5 months (HR, 0.785; P = .092), and in patients with AML with 20% to 30% blasts was 14.5 vs 14.7 months (HR, 1.107; P = .664). In a post hoc analysis, median OS in the higher-risk MDS cohort for patients receiving >3 cycles was 23.8 vs 20.6 months (P = .021) and for >6 cycles was 27.1 vs 22.5 months (P = .008). No new safety signals were identified, and the azacitidine dose intensity was maintained. Common hematologic grade ≥3 treatment emergent adverse events were anemia (33% vs 34%), neutropenia (31% vs 33%), and thrombocytopenia (30% vs 30%). These results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of continuing therapy for >3 cycles. The trial was registered on clinicaltrials.gov as #NCT03268954.

18 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
MKMarina Konopleva
Marina Konopleva
CRChristoph Röllig
Christoph Röllig
JCJamie Cavenagh
Jamie Cavenagh
DDDries Deeren
Dries Deeren
LGLarisa Girshova
Larisa Girshova
Andrew H WeiAndrew H Wei
Andrew H Wei
The phase III MIRROS trial (NCT02545283) evaluated the efficacy and safety of the small-molecule MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory acute myeloid leukemia (R/R AML). Adults (N=447) with R/R AML whose disease relapsed or was refractory after ≤2 prior induction regimens as initial treatment or following salvage chemotherapy regimen, with Eastern Cooperative Oncology Group performance status ≤2 were enrolled regardless of TP53 mutation status and randomly assigned 2:1 to idasanutlin 300 mg or placebo orally twice daily plus cytarabine 1 g/m2 intravenously on days 1 to 5 of 28-day cycles. At primary analysis (cutoff, November 2019), 436 patients were enrolled, including 355 in the TP53 wild-type intention-to-treat (TP53WT-ITT) population. The primary endpoint, overall survival in the TP53WT-ITT population, was not met (median, 8.3 vs 9.1 months with idasanutlin-cytarabine vs placebo-cytarabine; stratified hazard ratio, 1.08; 95% CI, 0.81-1.45; p = .58). The complete remission (CR) rate, a key secondary endpoint, was 20.3% vs 17.1% (odds ratio [OR], 1.23; 95% CI, 0.70-2.18). The overall response rate (ORR) was 38.8% vs 22.0% (OR, 2.25; 95% CI, 1.36-3.72). Common any-grade adverse events (≥10% incidence in any arm) were diarrhea (87.0% vs 32.9%), febrile neutropenia (52.8% vs 49.3%), and nausea (52.5% vs 31.5%). In summary, despite improved ORR, adding idasanutlin to cytarabine did not improve overall survival or CR rates in patients with R/R AML.

5 September 2024 in Leukemia
Verified
Journal Article
Open access
PDF file
JWJIANXIANG WANG
JIANXIANG WANG
BJBin Jiang
Bin Jiang
JLJian Li
Jian Li
LLLigen Liu
Ligen Liu
XDXin Du
Xin Du
NHNahla Hasabou
Nahla Hasabou
The phase 3 COMMODORE trial evaluated gilteritinib versus salvage chemotherapy (SC) in a predominantly Asian relapsed/refractory (R/R) FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML) patient population. The primary endpoint was overall survival (OS); secondary endpoints included event-free survival (EFS) and complete remission (CR) rate. As of June 30, 2020 (interim analysis: 32.2 months after study initiation), 234 patients were randomized (gilteritinib, n = 116; SC, n = 118). Median OS was significantly longer with gilteritinib versus SC (9.6 vs. 5.0 months; HR 0.566 [95% CI: 0.392, 0.818]; p = 0.00211) with a median follow-up of 10.3 months. Median EFS was also significantly longer with gilteritinib (2.8 vs. 0.6 months; HR 0.551 [95% CI: 0.395, 0.769]; p = 0.00004). CR rates with gilteritinib and SC were 16.4% and 10.2%, respectively; composite CR rates were 50.0% and 20.3%, respectively. Exposure-adjusted grade ≥3 adverse event (AE) rates were lower with gilteritinib (58.38 events/patient-year [E/PY]) versus SC (168.30 E/PY). Common AEs with gilteritinib were anemia (77.9%) and thrombocytopenia (45.1%). Gilteritinib plasma concentration peaked ~4 h postdose; ~3-fold accumulation occurred with multiple dosing. The COMMODORE trial demonstrated that gilteritinib significantly improved OS and EFS in predominantly Asian patients, validating the outcomes of gilteritinib from the ADMIRAL trial in R/R FLT3mut+ AML.

1 May 2021 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
ASAleksina Shatilova
Aleksina Shatilova
LGLarisa Girshova
Larisa Girshova
DZDaniil Zaytsev
Daniil Zaytsev
IBIrina Budaeva
Irina Budaeva
YMYuliya Mirolyubova
Yuliya Mirolyubova
AZAndrey Zaritskiy
Andrey Zaritskiy
Background: Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available literature data about diagnosis and management of MS is summarized in the article. The role of chemotherapy, radiation therapy, surgery and bone marrow transplantation in the treatment is discussed. Polychemotherapy and allogeneic bone marrow transplantation were suggested to be the optimal treatment strategy of MS of the gynecological tract. The use of new targeted agents results in promising clinical data. Case presentation: We are presenting a rare clinical case of a MS of the uterine cervix with concomitant bone marrow involvement and describe all the peculiarities of the clinical course, diagnosis, and treatment. The patient received chemotherapy followed by allogeneic bone marrow transplantation. The pre-transplant therapy allowed us to perform allogeneic bone marrow transplantation with the deepest response possible: complete PET-negative and MRD-negative remission of the disease. Conclusions: MS remains a subject of discussion regarding its diagnostic and therapeutic aspects. The use of novel targeting agents can be perspective option for patient with extramedullary disease.

12 November 2021 in Biological Communications
Verified
Journal Article
Closed access
PDF file
VGVasily Golotin
Vasily Golotin
EBEkaterina Belotserkovskaya
Ekaterina Belotserkovskaya
LGLarisa Girshova
Larisa Girshova
APAlexey Petukhov
Alexey Petukhov
AZAndrey Zaritsky
Andrey Zaritsky
Oleg DemidovOleg Demidov
Oleg Demidov
Recently wild-type p53-induced phosphatase was implicated in the pathogenesis of acute myeloid leukemia (AML) and “pre-leukemia” myeloproliferative conditions. Here we decided to check how the strategy directed to phosphatase inhibition affected sensitivity to conventional chemotherapy. All experiments were conducted on AML cell lines cultivated in vitro. The levels of wild-type p53-induced phosphatase vary in different AML cell lines. The chemical compound GSK2830371 reduced levels of phosphatase and diminished its activity. GSK2830371 did not significantly change the cell cycle distribution of AML cells when used alone or in combination with the anti-cancer chemotherapeutic drug Cytosar but increased caspase-dependent PARP1 cleavage. In contrast with previous studies, we did not observe the negative effect of phosphatase activity inhibition and depletion on cells when a chemical inhibitor was used as monotherapy. Using a combination of GSK2830371 with Cytosar we were able to reduce the threshold of chemotherapy-dependent cytotoxicity and more efficiently eliminate leukemic cells. We propose considering inhibition of wild-type p53-induced phosphatase as a prospective strategy in improving anti-AML therapy.

16 November 2012 in Blood
Verified
Journal Article
Open access
LGLarisa Girshova
Larisa Girshova
EREkaterina Romanova
Ekaterina Romanova
IKIrina Kholopova
Irina Kholopova
TNTatiana Nikulina
Tatiana Nikulina
JMJulia Mirolubova
Julia Mirolubova
AZAndrey Zaritskiy
Andrey Zaritskiy
Abstract 4345 Myeloid sarcoma (MS) is an extramedullary tumor composed of immature myeloid cells. Development of myeloid sarcoma may precede or accompany to AML, CML and other myeloproliferative diseases or myelodysplastic syndrome. About 95% of patients with isolated myeloid sarcoma develop AML within 1–48 months. Sites most commonly affected with myeloid sarcoma are bones, lymph nodes, skin and soft tissue. Isolated myeloid sarcoma of the breast is rare. There is no consensus on the choice of the optimal treatment strategy of primary extramedullary MS at the moment. However, there is evidence of the benefit of systemic chemotherapy, despite the localized nature of this disease. The patient is 30 years old female. The tumor of left breast 3.5 * 2.5 cm first time was identified in 07.2011. It was asymptomatic. Histological examination of the tumor revealed myeloid sarcoma (high expression of SD7, CD34, CD38, CD117, TDT, nucleophosmin, BCL-2, the heterogeneous expression of MPO and a low CD5 expression). MRI with contrast revealed 5 lesions of the left breast with different types of accumulation of contrast. According to CT scan of the thorax, abdomen, pelvis and MRI of the brain no other pathologic lesions have been identified. No abnormalities were also found during examination of peripheral blood and bone marrow. No expression of fusion genes, target gene mutations and abnormal expression of WT1 were revealed during molecular genetic examinations. Bone marrow cytogenetics was normal. The standard induction chemotherapy “7+3” regimen was conducted. 80% reduction of the left breast lesions (according to MRI, ultrasound) was achieved after the first treatment course. This course was followed by HDAC (1 cycle) and local radiotherapy (27 Gray) with complete clinical and radiological response according by PET. PET performed after therapy did not reveal metabolically active tissue in the breast. Second HDAC was used as a consolidation. According to the results of the control MRI remains a single fibrotic lesion in the left breast tissue, PET negative. At present, the patient clinically well for three months from the end of the last HiDAC. A complete remission continues for 7 months. We continue our observation In conclusion, myeloid sarcoma can occasionally involve the breast as an isolated mass in patients without a history or subsequent development of AML. Histologically, myeloid sarcoma can mimic a number of other neoplasms, but especially various types of lymphoma and breast carcinoma, and it can be easily misdiagnosed without an immunophenotypic workup. It remains to be determined whether chemoradiotherapy is superior to chemotherapy alone. In our case, we administered AML chemotherapy and incorporated local radiotherapy as well. Response assessment was performed by breast MRI and PET scans. Timely start of therapy and an adequate volume of therapy allow to achieve complete response in patients with myeloid sarcoma.